#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=5 .
1-1	0-1	5	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Tropism of YFV
2-1	4-11	Tropism	abstract[2]	new[2]	coref	3-13[9_2]
2-2	12-14	of	abstract[2]	new[2]	_	_
2-3	15-18	YFV	abstract[2]|abstract	new[2]|new	coref	3-8

#Text=In humans , after transcutaneous inoculation , YFV exhibits broad patterns of tissue tropism and is disseminated systemically via infection of multiple white cell subsets .
3-1	19-21	In	_	_	_	_
3-2	22-28	humans	person	new	coref	5-8[29_0]
3-3	29-30	,	_	_	_	_
3-4	31-36	after	_	_	_	_
3-5	37-51	transcutaneous	event[5]	new[5]	_	_
3-6	52-63	inoculation	event[5]	new[5]	_	_
3-7	64-65	,	_	_	_	_
3-8	66-69	YFV	abstract	giv	coref	4-34
3-9	70-78	exhibits	_	_	_	_
3-10	79-84	broad	abstract[7]	new[7]	_	_
3-11	85-93	patterns	abstract[7]	new[7]	_	_
3-12	94-96	of	abstract[7]	new[7]	_	_
3-13	97-103	tissue	abstract[7]|object|abstract[9]	new[7]|new|giv[9]	coref|coref|coref|coref	4-4[15_9]|4-28[23_0]|4-4[15_9]|4-28[23_0]
3-14	104-111	tropism	abstract[7]|abstract[9]	new[7]|giv[9]	_	_
3-15	112-115	and	_	_	_	_
3-16	116-118	is	_	_	_	_
3-17	119-131	disseminated	_	_	_	_
3-18	132-144	systemically	_	_	_	_
3-19	145-148	via	_	_	_	_
3-20	149-158	infection	event[10]	new[10]	coref	6-36[44_10]
3-21	159-161	of	event[10]	new[10]	_	_
3-22	162-170	multiple	event[10]|abstract[12]	new[10]|new[12]	_	_
3-23	171-176	white	event[10]|abstract[12]	new[10]|new[12]	_	_
3-24	177-181	cell	event[10]|place|abstract[12]	new[10]|new|new[12]	_	_
3-25	182-189	subsets	event[10]|abstract[12]	new[10]|new[12]	_	_
3-26	190-191	.	_	_	_	_

#Text=With respect to organ tropism , the liver is the primary target , although the heart , kidneys , liver , spleen , and less frequently , the brain tissue , can support YFV replication .
4-1	192-196	With	_	_	_	_
4-2	197-204	respect	abstract[13]	new[13]	_	_
4-3	205-207	to	abstract[13]	new[13]	_	_
4-4	208-213	organ	abstract[13]|abstract|abstract[15]	new[13]|new|giv[15]	_	_
4-5	214-221	tropism	abstract[13]|abstract[15]	new[13]|giv[15]	_	_
4-6	222-223	,	_	_	_	_
4-7	224-227	the	object[16]	new[16]	coref	4-10[17_16]
4-8	228-233	liver	object[16]	new[16]	_	_
4-9	234-236	is	_	_	_	_
4-10	237-240	the	object[17]	giv[17]	coref	4-20[0_17]
4-11	241-248	primary	object[17]	giv[17]	_	_
4-12	249-255	target	object[17]	giv[17]	_	_
4-13	256-257	,	_	_	_	_
4-14	258-266	although	_	_	_	_
4-15	267-270	the	object[18]	new[18]	_	_
4-16	271-276	heart	object[18]	new[18]	_	_
4-17	277-278	,	_	_	_	_
4-18	279-286	kidneys	place	new	_	_
4-19	287-288	,	_	_	_	_
4-20	289-294	liver	object	giv	_	_
4-21	295-296	,	_	_	_	_
4-22	297-303	spleen	object	new	_	_
4-23	304-305	,	_	_	_	_
4-24	306-309	and	_	_	_	_
4-25	310-314	less	_	_	_	_
4-26	315-325	frequently	_	_	_	_
4-27	326-327	,	_	_	_	_
4-28	328-331	the	object[23]	giv[23]	coref	14-19[109_23]
4-29	332-337	brain	object|object[23]	new|giv[23]	coref	14-11[105_0]
4-30	338-344	tissue	object[23]	giv[23]	_	_
4-31	345-346	,	_	_	_	_
4-32	347-350	can	_	_	_	_
4-33	351-358	support	_	_	_	_
4-34	359-362	YFV	abstract|abstract[25]	giv|new[25]	coref|coref|coref|coref	5-6|11-13[0_25]|5-6|11-13[0_25]
4-35	363-374	replication	abstract[25]	new[25]	_	_
4-36	375-376	.	_	_	_	_

#Text=The natural host range of YFV includes humans , non-human primates and mosquitos .
5-1	377-380	The	abstract[27]	new[27]	_	_
5-2	381-388	natural	abstract[27]	new[27]	_	_
5-3	389-393	host	person|abstract[27]	new|new[27]	coref	9-6
5-4	394-399	range	abstract[27]	new[27]	_	_
5-5	400-402	of	abstract[27]	new[27]	_	_
5-6	403-406	YFV	abstract[27]|abstract	new[27]|giv	coref	6-34
5-7	407-415	includes	_	_	_	_
5-8	416-422	humans	person[29]	giv[29]	coref	9-29[0_29]
5-9	423-424	,	person[29]	giv[29]	_	_
5-10	425-434	non-human	person[29]|animal[30]	giv[29]|new[30]	coref	8-16[56_30]
5-11	435-443	primates	person[29]|animal[30]	giv[29]|new[30]	_	_
5-12	444-447	and	person[29]	giv[29]	_	_
5-13	448-457	mosquitos	person[29]|animal	giv[29]|new	coref	17-7
5-14	458-459	.	_	_	_	_

#Text=Additionally , wild animals from the diverse orders Artiodactyla , Carnivora and the superorder Xenarthra have been reported to be serologically positive for anti-YFV antibodies , and the elicitation of antibody responses against YFV indicates a potentially productive infection within these species , indicating that diverse mammalian species could represent YFV potential reservoirs ( see Section 8.3 ) .
6-1	460-472	Additionally	_	_	_	_
6-2	473-474	,	_	_	_	_
6-3	475-479	wild	animal[32]	new[32]	coref	12-16[89_32]
6-4	480-487	animals	animal[32]	new[32]	_	_
6-5	488-492	from	animal[32]	new[32]	_	_
6-6	493-496	the	animal[32]|abstract[33]	new[32]|new[33]	_	_
6-7	497-504	diverse	animal[32]|abstract[33]	new[32]|new[33]	_	_
6-8	505-511	orders	animal[32]|abstract[33]	new[32]|new[33]	_	_
6-9	512-524	Artiodactyla	animal[32]|animal	new[32]|new	_	_
6-10	525-526	,	animal[32]	new[32]	_	_
6-11	527-536	Carnivora	animal[32]|animal	new[32]|new	_	_
6-12	537-540	and	animal[32]	new[32]	_	_
6-13	541-544	the	animal[32]|animal[37]	new[32]|new[37]	_	_
6-14	545-555	superorder	animal[32]|abstract|animal[37]	new[32]|new|new[37]	_	_
6-15	556-565	Xenarthra	animal[32]|animal[37]	new[32]|new[37]	_	_
6-16	566-570	have	_	_	_	_
6-17	571-575	been	_	_	_	_
6-18	576-584	reported	_	_	_	_
6-19	585-587	to	_	_	_	_
6-20	588-590	be	_	_	_	_
6-21	591-604	serologically	_	_	_	_
6-22	605-613	positive	_	_	_	_
6-23	614-617	for	_	_	_	_
6-24	618-626	anti-YFV	abstract|object[39]	new|new[39]	_	_
6-25	627-637	antibodies	object[39]	new[39]	_	_
6-26	638-639	,	_	_	_	_
6-27	640-643	and	_	_	_	_
6-28	644-647	the	event[40]	new[40]	_	_
6-29	648-659	elicitation	event[40]	new[40]	_	_
6-30	660-662	of	event[40]	new[40]	_	_
6-31	663-671	antibody	event[40]|substance|abstract[42]	new[40]|new|new[42]	_	_
6-32	672-681	responses	event[40]|abstract[42]	new[40]|new[42]	_	_
6-33	682-689	against	event[40]|abstract[42]	new[40]|new[42]	_	_
6-34	690-693	YFV	event[40]|abstract[42]|abstract	new[40]|new[42]|giv	coref	7-4
6-35	694-703	indicates	_	_	_	_
6-36	704-705	a	event[44]	giv[44]	_	_
6-37	706-717	potentially	event[44]	giv[44]	_	_
6-38	718-728	productive	event[44]	giv[44]	_	_
6-39	729-738	infection	event[44]	giv[44]	_	_
6-40	739-745	within	event[44]	giv[44]	_	_
6-41	746-751	these	event[44]|animal[45]	giv[44]|new[45]	coref	6-46[47_45]
6-42	752-759	species	event[44]|animal[45]	giv[44]|new[45]	_	_
6-43	760-761	,	_	_	_	_
6-44	762-772	indicating	_	_	_	_
6-45	773-777	that	_	_	_	_
6-46	778-785	diverse	animal[47]	giv[47]	coref	17-16[135_47]
6-47	786-795	mammalian	animal|animal[47]	new|giv[47]	_	_
6-48	796-803	species	animal[47]	giv[47]	_	_
6-49	804-809	could	_	_	_	_
6-50	810-819	represent	_	_	_	_
6-51	820-823	YFV	abstract[48]	new[48]	coref	11-11[79_48]
6-52	824-833	potential	abstract[48]	new[48]	_	_
6-53	834-844	reservoirs	abstract[48]	new[48]	_	_
6-54	845-846	(	_	_	_	_
6-55	847-850	see	_	_	_	_
6-56	851-858	Section	abstract[49]	new[49]	_	_
6-57	859-862	8.3	abstract[49]	new[49]	_	_
6-58	863-864	)	_	_	_	_
6-59	865-866	.	_	_	_	_

#Text=Mouse Models for YFV
7-1	867-872	Mouse	abstract[50]	new[50]	coref	11-7[76_50]
7-2	873-879	Models	abstract[50]	new[50]	_	_
7-3	880-883	for	abstract[50]	new[50]	_	_
7-4	884-887	YFV	abstract[50]|abstract	new[50]|giv	coref	8-1

#Text=YFV research is currently limited as it remains challenging and expensive to establish workflows with non-human primates .
8-1	888-891	YFV	abstract|abstract[53]	giv|new[53]	ana|coref|ana|coref	8-7[0_53]|9-2|8-7[0_53]|9-2
8-2	892-900	research	abstract[53]	new[53]	_	_
8-3	901-903	is	_	_	_	_
8-4	904-913	currently	_	_	_	_
8-5	914-921	limited	_	_	_	_
8-6	922-924	as	_	_	_	_
8-7	925-927	it	abstract	giv	_	_
8-8	928-935	remains	_	_	_	_
8-9	936-947	challenging	_	_	_	_
8-10	948-951	and	_	_	_	_
8-11	952-961	expensive	_	_	_	_
8-12	962-964	to	_	_	_	_
8-13	965-974	establish	_	_	_	_
8-14	975-984	workflows	abstract	new	_	_
8-15	985-989	with	_	_	_	_
8-16	990-999	non-human	animal[56]	giv[56]	coref	13-14[0_56]
8-17	1000-1008	primates	animal[56]	giv[56]	_	_
8-18	1009-1010	.	_	_	_	_

#Text=While YFV has a limited host species-tropism , artificial infection of laboratory mice and hamsters is possible , although the course of disease differs from that observed in humans .
9-1	1011-1016	While	_	_	_	_
9-2	1017-1020	YFV	abstract	giv	coref	10-17
9-3	1021-1024	has	_	_	_	_
9-4	1025-1026	a	event[59]	new[59]	coref	10-17[69_59]
9-5	1027-1034	limited	event[59]	new[59]	_	_
9-6	1035-1039	host	person|event[59]	giv|new[59]	_	_
9-7	1040-1055	species-tropism	event[59]	new[59]	_	_
9-8	1056-1057	,	event[59]	new[59]	_	_
9-9	1058-1068	artificial	event[59]	new[59]	_	_
9-10	1069-1078	infection	event[59]	new[59]	_	_
9-11	1079-1081	of	event[59]	new[59]	_	_
9-12	1082-1092	laboratory	event[59]|animal[60]	new[59]|new[60]	coref	10-12[0_60]
9-13	1093-1097	mice	event[59]|animal[60]	new[59]|new[60]	_	_
9-14	1098-1101	and	event[59]	new[59]	_	_
9-15	1102-1110	hamsters	event[59]|animal	new[59]|new	_	_
9-16	1111-1113	is	_	_	_	_
9-17	1114-1122	possible	_	_	_	_
9-18	1123-1124	,	_	_	_	_
9-19	1125-1133	although	_	_	_	_
9-20	1134-1137	the	abstract[62]	new[62]	_	_
9-21	1138-1144	course	abstract[62]	new[62]	_	_
9-22	1145-1147	of	abstract[62]	new[62]	_	_
9-23	1148-1155	disease	abstract[62]|abstract	new[62]|new	coref	21-21
9-24	1156-1163	differs	_	_	_	_
9-25	1164-1168	from	_	_	_	_
9-26	1169-1173	that	_	_	_	_
9-27	1174-1182	observed	_	_	_	_
9-28	1183-1185	in	_	_	_	_
9-29	1186-1192	humans	person	giv	coref	13-16
9-30	1193-1194	.	_	_	_	_

#Text=Nevertheless , a number of studies in genetically modified or humanized mice have yielded insights into YFV infection and dissemination in vivo .
10-1	1195-1207	Nevertheless	_	_	_	_
10-2	1208-1209	,	_	_	_	_
10-3	1210-1211	a	abstract[65]	new[65]	coref	24-3[212_65]
10-4	1212-1218	number	abstract[65]	new[65]	_	_
10-5	1219-1221	of	abstract[65]	new[65]	_	_
10-6	1222-1229	studies	abstract[65]	new[65]	_	_
10-7	1230-1232	in	_	_	_	_
10-8	1233-1244	genetically	_	_	_	_
10-9	1245-1253	modified	_	_	_	_
10-10	1254-1256	or	_	_	_	_
10-11	1257-1266	humanized	_	_	_	_
10-12	1267-1271	mice	animal	giv	coref	12-1[85_0]
10-13	1272-1276	have	_	_	_	_
10-14	1277-1284	yielded	_	_	_	_
10-15	1285-1293	insights	abstract[67]	new[67]	_	_
10-16	1294-1298	into	abstract[67]	new[67]	_	_
10-17	1299-1302	YFV	abstract[67]|object|event[69]|abstract[70]	new[67]|giv|giv[69]|new[70]	coref|coref|coref|coref|coref|coref|coref|coref|coref	11-12|12-23[92_69]|21-1[174_70]|11-12|12-23[92_69]|21-1[174_70]|11-12|12-23[92_69]|21-1[174_70]
10-18	1303-1312	infection	abstract[67]|event[69]|abstract[70]	new[67]|giv[69]|new[70]	_	_
10-19	1313-1316	and	abstract[67]|abstract[70]	new[67]|new[70]	_	_
10-20	1317-1330	dissemination	abstract[67]|abstract[70]|abstract[71]	new[67]|new[70]|new[71]	coref	11-4[74_71]
10-21	1331-1333	in	abstract[67]|abstract[70]|abstract[71]	new[67]|new[70]|new[71]	_	_
10-22	1334-1338	vivo	abstract[67]|abstract[70]|abstract[71]	new[67]|new[70]|new[71]	_	_
10-23	1339-1340	.	_	_	_	_

#Text=Single cell-tracking of YFV-17D dissemination in different mouse models identified novel YFV replication reservoirs in secondary lymphoid compartments , with hematopoietic STAT1 knockout increasing virus-induced pathogenicity .
11-1	1341-1347	Single	object[72]	new[72]	_	_
11-2	1348-1361	cell-tracking	object[72]	new[72]	_	_
11-3	1362-1364	of	object[72]	new[72]	_	_
11-4	1365-1372	YFV-17D	object[72]|organization|abstract[74]	new[72]|new|giv[74]	coref|coref|coref|coref	14-17|17-4[0_74]|14-17|17-4[0_74]
11-5	1373-1386	dissemination	object[72]|abstract[74]	new[72]|giv[74]	_	_
11-6	1387-1389	in	object[72]|abstract[74]	new[72]|giv[74]	_	_
11-7	1390-1399	different	object[72]|abstract[74]|abstract[76]	new[72]|giv[74]|giv[76]	coref	20-32[172_76]
11-8	1400-1405	mouse	object[72]|abstract[74]|animal|abstract[76]	new[72]|giv[74]|new|giv[76]	coref	20-32
11-9	1406-1412	models	object[72]|abstract[74]|abstract[76]	new[72]|giv[74]|giv[76]	_	_
11-10	1413-1423	identified	_	_	_	_
11-11	1424-1429	novel	abstract[79]	giv[79]	_	_
11-12	1430-1433	YFV	abstract|abstract[79]	giv|giv[79]	coref	12-24
11-13	1434-1445	replication	abstract|abstract[79]	giv|giv[79]	coref	22-17[193_0]
11-14	1446-1456	reservoirs	abstract[79]	giv[79]	_	_
11-15	1457-1459	in	abstract[79]	giv[79]	_	_
11-16	1460-1469	secondary	abstract[79]|place[81]	giv[79]|new[81]	coref	12-29[93_81]
11-17	1470-1478	lymphoid	abstract[79]|object|place[81]	giv[79]|new|new[81]	_	_
11-18	1479-1491	compartments	abstract[79]|place[81]	giv[79]|new[81]	_	_
11-19	1492-1493	,	abstract[79]	giv[79]	_	_
11-20	1494-1498	with	abstract[79]	giv[79]	_	_
11-21	1499-1512	hematopoietic	abstract[79]|abstract[83]	giv[79]|new[83]	_	_
11-22	1513-1518	STAT1	abstract[79]|abstract|abstract[83]	giv[79]|new|new[83]	coref	21-7
11-23	1519-1527	knockout	abstract[79]|abstract[83]	giv[79]|new[83]	_	_
11-24	1528-1538	increasing	_	_	_	_
11-25	1539-1552	virus-induced	abstract[84]	new[84]	_	_
11-26	1553-1566	pathogenicity	abstract[84]	new[84]	_	_
11-27	1567-1568	.	_	_	_	_

#Text=Double-humanized mice have been developed , possessing both human immune systems and hepatocytes , and these animals represent ideal tools for monitoring systemic YFV infection in vivo as both compartments are permissive for YFV .
12-1	1569-1585	Double-humanized	animal[85]	giv[85]	coref	15-22[119_85]
12-2	1586-1590	mice	animal[85]	giv[85]	_	_
12-3	1591-1595	have	_	_	_	_
12-4	1596-1600	been	_	_	_	_
12-5	1601-1610	developed	_	_	_	_
12-6	1611-1612	,	_	_	_	_
12-7	1613-1623	possessing	_	_	_	_
12-8	1624-1628	both	abstract[87]	new[87]	_	_
12-9	1629-1634	human	abstract[87]	new[87]	_	_
12-10	1635-1641	immune	abstract|abstract[87]	new|new[87]	_	_
12-11	1642-1649	systems	abstract[87]	new[87]	_	_
12-12	1650-1653	and	_	_	_	_
12-13	1654-1665	hepatocytes	substance	new	_	_
12-14	1666-1667	,	_	_	_	_
12-15	1668-1671	and	_	_	_	_
12-16	1672-1677	these	animal[89]	giv[89]	_	_
12-17	1678-1685	animals	animal[89]	giv[89]	_	_
12-18	1686-1695	represent	_	_	_	_
12-19	1696-1701	ideal	object[90]	new[90]	_	_
12-20	1702-1707	tools	object[90]	new[90]	_	_
12-21	1708-1711	for	_	_	_	_
12-22	1712-1722	monitoring	_	_	_	_
12-23	1723-1731	systemic	event[92]	giv[92]	coref	19-14[148_92]
12-24	1732-1735	YFV	object|event[92]	giv|giv[92]	coref	12-34
12-25	1736-1745	infection	event[92]	giv[92]	_	_
12-26	1746-1748	in	event[92]	giv[92]	_	_
12-27	1749-1753	vivo	event[92]	giv[92]	_	_
12-28	1754-1756	as	_	_	_	_
12-29	1757-1761	both	place[93]	giv[93]	_	_
12-30	1762-1774	compartments	place[93]	giv[93]	_	_
12-31	1775-1778	are	_	_	_	_
12-32	1779-1789	permissive	_	_	_	_
12-33	1790-1793	for	_	_	_	_
12-34	1794-1797	YFV	abstract	giv	coref	13-6
12-35	1798-1799	.	_	_	_	_

#Text=In addition to hepatotropism , YFV can also be neurotropic in rodents , primates and humans .
13-1	1800-1802	In	_	_	_	_
13-2	1803-1811	addition	_	_	_	_
13-3	1812-1814	to	_	_	_	_
13-4	1815-1828	hepatotropism	abstract	new	_	_
13-5	1829-1830	,	_	_	_	_
13-6	1831-1834	YFV	abstract	giv	coref	13-10[97_0]
13-7	1835-1838	can	_	_	_	_
13-8	1839-1843	also	_	_	_	_
13-9	1844-1846	be	_	_	_	_
13-10	1847-1858	neurotropic	abstract[97]	giv[97]	coref	22-20[194_97]
13-11	1859-1861	in	abstract[97]	giv[97]	_	_
13-12	1862-1869	rodents	abstract[97]|animal	giv[97]|new	_	_
13-13	1870-1871	,	abstract[97]	giv[97]	_	_
13-14	1872-1880	primates	abstract[97]|animal	giv[97]|giv	_	_
13-15	1881-1884	and	abstract[97]	giv[97]	_	_
13-16	1885-1891	humans	abstract[97]|person	giv[97]|giv	coref	21-27
13-17	1892-1893	.	_	_	_	_

#Text=In contrast to polio virus and reovirus , which infect the brain via the CNS , YFV-17D infects brain tissue by crossing the blood-brain barrier .
14-1	1894-1896	In	_	_	_	_
14-2	1897-1905	contrast	abstract[101]	new[101]	_	_
14-3	1906-1908	to	abstract[101]	new[101]	_	_
14-4	1909-1914	polio	abstract[101]|person|abstract[103]	new[101]|new|new[103]	coref|coref	17-13[133_103]|17-13[133_103]
14-5	1915-1920	virus	abstract[101]|abstract[103]	new[101]|new[103]	_	_
14-6	1921-1924	and	abstract[101]	new[101]	_	_
14-7	1925-1933	reovirus	abstract[101]|abstract	new[101]|new	_	_
14-8	1934-1935	,	_	_	_	_
14-9	1936-1941	which	_	_	_	_
14-10	1942-1948	infect	_	_	_	_
14-11	1949-1952	the	object[105]	giv[105]	coref	14-19[0_105]
14-12	1953-1958	brain	object[105]	giv[105]	_	_
14-13	1959-1962	via	object[105]	giv[105]	_	_
14-14	1963-1966	the	object[105]|place[106]	giv[105]|new[106]	_	_
14-15	1967-1970	CNS	object[105]|place[106]	giv[105]|new[106]	_	_
14-16	1971-1972	,	_	_	_	_
14-17	1973-1980	YFV-17D	abstract	giv	coref	19-6
14-18	1981-1988	infects	_	_	_	_
14-19	1989-1994	brain	object|object[109]	giv|giv[109]	coref|coref	18-11[0_109]|18-11[0_109]
14-20	1995-2001	tissue	object[109]	giv[109]	_	_
14-21	2002-2004	by	_	_	_	_
14-22	2005-2013	crossing	_	_	_	_
14-23	2014-2017	the	object[110]	new[110]	_	_
14-24	2018-2029	blood-brain	object[110]	new[110]	_	_
14-25	2030-2037	barrier	object[110]	new[110]	_	_
14-26	2038-2039	.	_	_	_	_

#Text=A mouse-neurovirulent strain ( SPYF ) based on the Porterfield 17D ( PYF17D ) strain was derived by additional passaging in SCID mice , exhibiting enhanced neurovirulence and neuroinvasiveness .
15-1	2040-2041	A	abstract[111]	new[111]	appos	15-5[0_111]
15-2	2042-2061	mouse-neurovirulent	abstract[111]	new[111]	_	_
15-3	2062-2068	strain	abstract[111]	new[111]	_	_
15-4	2069-2070	(	_	_	_	_
15-5	2071-2075	SPYF	abstract	giv	_	_
15-6	2076-2077	)	_	_	_	_
15-7	2078-2083	based	_	_	_	_
15-8	2084-2086	on	_	_	_	_
15-9	2087-2090	the	abstract[114]	new[114]	appos	15-13[0_114]
15-10	2091-2102	Porterfield	person|abstract[114]	new|new[114]	_	_
15-11	2103-2106	17D	abstract[114]	new[114]	_	_
15-12	2107-2108	(	_	_	_	_
15-13	2109-2115	PYF17D	abstract	giv	_	_
15-14	2116-2117	)	_	_	_	_
15-15	2118-2124	strain	abstract	new	_	_
15-16	2125-2128	was	_	_	_	_
15-17	2129-2136	derived	_	_	_	_
15-18	2137-2139	by	_	_	_	_
15-19	2140-2150	additional	place[117]	new[117]	_	_
15-20	2151-2160	passaging	place[117]	new[117]	_	_
15-21	2161-2163	in	place[117]	new[117]	_	_
15-22	2164-2168	SCID	place[117]|animal|animal[119]	new[117]|new|giv[119]	coref|coref	19-9[147_119]|19-9[147_119]
15-23	2169-2173	mice	place[117]|animal[119]	new[117]|giv[119]	_	_
15-24	2174-2175	,	_	_	_	_
15-25	2176-2186	exhibiting	_	_	_	_
15-26	2187-2195	enhanced	abstract[120]	new[120]	_	_
15-27	2196-2210	neurovirulence	abstract[120]	new[120]	_	_
15-28	2211-2214	and	_	_	_	_
15-29	2215-2232	neuroinvasiveness	abstract	new	_	_
15-30	2233-2234	.	_	_	_	_

#Text=This enhanced neurotopism was correlated with 13 amino acid substitutions , five of which were located in the E protein .
16-1	2235-2239	This	abstract[122]	new[122]	_	_
16-2	2240-2248	enhanced	abstract[122]	new[122]	_	_
16-3	2249-2260	neurotopism	abstract[122]	new[122]	_	_
16-4	2261-2264	was	_	_	_	_
16-5	2265-2275	correlated	_	_	_	_
16-6	2276-2280	with	_	_	_	_
16-7	2281-2283	13	abstract[124]	new[124]	ana	18-1[0_124]
16-8	2284-2289	amino	abstract[124]	new[124]	_	_
16-9	2290-2294	acid	substance|abstract[124]	new|new[124]	_	_
16-10	2295-2308	substitutions	abstract[124]	new[124]	_	_
16-11	2309-2310	,	_	_	_	_
16-12	2311-2315	five	time	new	_	_
16-13	2316-2318	of	_	_	_	_
16-14	2319-2324	which	_	_	_	_
16-15	2325-2329	were	_	_	_	_
16-16	2330-2337	located	_	_	_	_
16-17	2338-2340	in	_	_	_	_
16-18	2341-2344	the	substance[127]	new[127]	_	_
16-19	2345-2346	E	person|substance[127]	new|new[127]	_	_
16-20	2347-2354	protein	substance[127]	new[127]	_	_
16-21	2355-2356	.	_	_	_	_

#Text=Arboviruses can encounter dissemination barriers in mosquitos , restricting the spreading of the virus within the vector species .
17-1	2357-2368	Arboviruses	object	new	_	_
17-2	2369-2372	can	_	_	_	_
17-3	2373-2382	encounter	_	_	_	_
17-4	2383-2396	dissemination	abstract|object[130]	giv|new[130]	coref|coref|coref|coref	18-10[140_130]|19-6[146_0]|18-10[140_130]|19-6[146_0]
17-5	2397-2405	barriers	object[130]	new[130]	_	_
17-6	2406-2408	in	object[130]	new[130]	_	_
17-7	2409-2418	mosquitos	object[130]|animal	new[130]|giv	_	_
17-8	2419-2420	,	_	_	_	_
17-9	2421-2432	restricting	_	_	_	_
17-10	2433-2436	the	abstract[132]	new[132]	_	_
17-11	2437-2446	spreading	abstract[132]	new[132]	_	_
17-12	2447-2449	of	abstract[132]	new[132]	_	_
17-13	2450-2453	the	abstract[132]|abstract[133]	new[132]|giv[133]	_	_
17-14	2454-2459	virus	abstract[132]|abstract[133]	new[132]|giv[133]	_	_
17-15	2460-2466	within	abstract[132]|abstract[133]	new[132]|giv[133]	_	_
17-16	2467-2470	the	abstract[132]|abstract[133]|animal[135]	new[132]|giv[133]|giv[135]	_	_
17-17	2471-2477	vector	abstract[132]|abstract[133]|animal|animal[135]	new[132]|giv[133]|new|giv[135]	_	_
17-18	2478-2485	species	abstract[132]|abstract[133]|animal[135]	new[132]|giv[133]|giv[135]	_	_
17-19	2486-2487	.	_	_	_	_

#Text=These include innate immunity related pathways as well as physical tissue barriers associated with the midgut and salivary glands .
18-1	2488-2493	These	abstract	giv	_	_
18-2	2494-2501	include	_	_	_	_
18-3	2502-2508	innate	abstract[137]	new[137]	_	_
18-4	2509-2517	immunity	abstract[137]	new[137]	_	_
18-5	2518-2525	related	place[138]	new[138]	_	_
18-6	2526-2534	pathways	place[138]	new[138]	_	_
18-7	2535-2537	as	_	_	_	_
18-8	2538-2542	well	_	_	_	_
18-9	2543-2545	as	_	_	_	_
18-10	2546-2554	physical	object[140]	giv[140]	coref	19-29[154_140]
18-11	2555-2561	tissue	object|object[140]	giv|giv[140]	_	_
18-12	2562-2570	barriers	object[140]	giv[140]	_	_
18-13	2571-2581	associated	_	_	_	_
18-14	2582-2586	with	_	_	_	_
18-15	2587-2590	the	place[141]	new[141]	_	_
18-16	2591-2597	midgut	place[141]	new[141]	_	_
18-17	2598-2601	and	_	_	_	_
18-18	2602-2610	salivary	person|object[143]	new|new[143]	_	_
18-19	2611-2617	glands	object[143]	new[143]	_	_
18-20	2618-2619	.	_	_	_	_

#Text=However , while patterns of YFV-17D dissemination in immunocompetent mice were restricted , infection of IFNAR knockout mice resulted in broad dissemination preceding viral clearance , indicating that no barriers to dissemination exist in the absence of type I IFN .
19-1	2620-2627	However	_	_	_	_
19-2	2628-2629	,	_	_	_	_
19-3	2630-2635	while	_	_	_	_
19-4	2636-2644	patterns	abstract[144]	new[144]	_	_
19-5	2645-2647	of	abstract[144]	new[144]	_	_
19-6	2648-2655	YFV-17D	abstract[144]|organization|abstract[146]	new[144]|giv|giv[146]	coref|coref|coref|coref	19-21[151_146]|20-13|19-21[151_146]|20-13
19-7	2656-2669	dissemination	abstract[144]|abstract[146]	new[144]|giv[146]	_	_
19-8	2670-2672	in	abstract[144]|abstract[146]	new[144]|giv[146]	_	_
19-9	2673-2688	immunocompetent	abstract[144]|abstract[146]|animal[147]	new[144]|giv[146]|giv[147]	coref	19-16[150_147]
19-10	2689-2693	mice	abstract[144]|abstract[146]|animal[147]	new[144]|giv[146]|giv[147]	_	_
19-11	2694-2698	were	_	_	_	_
19-12	2699-2709	restricted	_	_	_	_
19-13	2710-2711	,	_	_	_	_
19-14	2712-2721	infection	event[148]	giv[148]	coref	20-13[166_148]
19-15	2722-2724	of	event[148]	giv[148]	_	_
19-16	2725-2730	IFNAR	event[148]|animal|animal[150]	giv[148]|new|giv[150]	coref|coref	21-10[179_150]|21-10[179_150]
19-17	2731-2739	knockout	event[148]|animal[150]	giv[148]|giv[150]	_	_
19-18	2740-2744	mice	event[148]|animal[150]	giv[148]|giv[150]	_	_
19-19	2745-2753	resulted	_	_	_	_
19-20	2754-2756	in	_	_	_	_
19-21	2757-2762	broad	abstract[151]	giv[151]	coref	19-32[0_151]
19-22	2763-2776	dissemination	abstract[151]	giv[151]	_	_
19-23	2777-2786	preceding	_	_	_	_
19-24	2787-2792	viral	organization|event[153]	new|new[153]	coref|coref	22-17|22-17
19-25	2793-2802	clearance	event[153]	new[153]	_	_
19-26	2803-2804	,	_	_	_	_
19-27	2805-2815	indicating	_	_	_	_
19-28	2816-2820	that	_	_	_	_
19-29	2821-2823	no	object[154]	giv[154]	_	_
19-30	2824-2832	barriers	object[154]	giv[154]	_	_
19-31	2833-2835	to	object[154]	giv[154]	_	_
19-32	2836-2849	dissemination	object[154]|abstract	giv[154]|giv	coref	24-10[216_0]
19-33	2850-2855	exist	_	_	_	_
19-34	2856-2858	in	_	_	_	_
19-35	2859-2862	the	abstract[156]	new[156]	_	_
19-36	2863-2870	absence	abstract[156]	new[156]	_	_
19-37	2871-2873	of	abstract[156]	new[156]	_	_
19-38	2874-2878	type	abstract[156]|abstract	new[156]|new	appos	19-40
19-39	2879-2880	I	person	acc	ana	20-4
19-40	2881-2884	IFN	abstract	giv	ana	20-6
19-41	2885-2886	.	_	_	_	_

#Text=Furthermore , while I and II type IFNs contribute to control of YFV-17D infection , type III IFN was demonstrated to have immunomodulatory functions and was protective against YFV-17D neuroinvasion in mouse models .
20-1	2887-2898	Furthermore	_	_	_	_
20-2	2899-2900	,	_	_	_	_
20-3	2901-2906	while	_	_	_	_
20-4	2907-2908	I	person	giv	_	_
20-5	2909-2912	and	_	_	_	_
20-6	2913-2915	II	abstract	giv	coref	20-7
20-7	2916-2920	type	abstract	giv	coref	20-16[167_0]
20-8	2921-2925	IFNs	abstract	new	_	_
20-9	2926-2936	contribute	_	_	_	_
20-10	2937-2939	to	_	_	_	_
20-11	2940-2947	control	abstract[164]	new[164]	coref	24-14[0_164]
20-12	2948-2950	of	abstract[164]	new[164]	_	_
20-13	2951-2958	YFV-17D	abstract[164]|object|event[166]	new[164]|giv|giv[166]	coref|coref|coref|coref	20-29|21-14[181_166]|20-29|21-14[181_166]
20-14	2959-2968	infection	abstract[164]|event[166]	new[164]|giv[166]	_	_
20-15	2969-2970	,	_	_	_	_
20-16	2971-2975	type	abstract[167]	giv[167]	coref	22-12[0_167]
20-17	2976-2979	III	abstract[167]	giv[167]	_	_
20-18	2980-2983	IFN	abstract[167]	giv[167]	_	_
20-19	2984-2987	was	_	_	_	_
20-20	2988-3000	demonstrated	_	_	_	_
20-21	3001-3003	to	_	_	_	_
20-22	3004-3008	have	_	_	_	_
20-23	3009-3025	immunomodulatory	abstract[168]	new[168]	_	_
20-24	3026-3035	functions	abstract[168]	new[168]	_	_
20-25	3036-3039	and	_	_	_	_
20-26	3040-3043	was	_	_	_	_
20-27	3044-3054	protective	_	_	_	_
20-28	3055-3062	against	_	_	_	_
20-29	3063-3070	YFV-17D	abstract|abstract[170]	giv|new[170]	_	_
20-30	3071-3084	neuroinvasion	abstract[170]	new[170]	_	_
20-31	3085-3087	in	abstract[170]	new[170]	_	_
20-32	3088-3093	mouse	abstract[170]|animal|abstract[172]	new[170]|giv|giv[172]	coref|coref|coref|coref	24-4|25-13[223_172]|24-4|25-13[223_172]
20-33	3094-3100	models	abstract[170]|abstract[172]	new[170]|giv[172]	_	_
20-34	3101-3102	.	_	_	_	_

#Text=YFD-17D infection of IFN-α/β receptor and STAT1 signaling molecule deficient mice resulted in systemic viscerotropic infection : a course of disease which resembles that observed in humans rather than the typical encephalitic disease course commonly reported for mice .
21-1	3103-3110	YFD-17D	abstract[173]|abstract[174]	new[173]|giv[174]	_	_
21-2	3111-3120	infection	abstract[173]|abstract[174]	new[173]|giv[174]	_	_
21-3	3121-3123	of	abstract[173]|abstract[174]	new[173]|giv[174]	_	_
21-4	3124-3131	IFN-α/β	abstract[173]|abstract[174]|abstract|substance[176]	new[173]|giv[174]|new|new[176]	_	_
21-5	3132-3140	receptor	abstract[173]|abstract[174]|substance[176]	new[173]|giv[174]|new[176]	_	_
21-6	3141-3144	and	abstract[174]	giv[174]	_	_
21-7	3145-3150	STAT1	abstract[174]|substance|abstract[178]	giv[174]|giv|new[178]	_	_
21-8	3151-3160	signaling	abstract[174]|abstract[178]	giv[174]|new[178]	_	_
21-9	3161-3169	molecule	abstract[174]|abstract[178]	giv[174]|new[178]	_	_
21-10	3170-3179	deficient	animal[179]	giv[179]	coref	21-38[0_179]
21-11	3180-3184	mice	animal[179]	giv[179]	_	_
21-12	3185-3193	resulted	_	_	_	_
21-13	3194-3196	in	_	_	_	_
21-14	3197-3205	systemic	event[181]	giv[181]	_	_
21-15	3206-3219	viscerotropic	abstract|event[181]	new|giv[181]	_	_
21-16	3220-3229	infection	event[181]	giv[181]	_	_
21-17	3230-3231	:	_	_	_	_
21-18	3232-3233	a	abstract[182]	new[182]	coref	21-30[186_182]
21-19	3234-3240	course	abstract[182]	new[182]	_	_
21-20	3241-3243	of	abstract[182]	new[182]	_	_
21-21	3244-3251	disease	abstract[182]|abstract	new[182]|giv	coref	21-33
21-22	3252-3257	which	_	_	_	_
21-23	3258-3267	resembles	_	_	_	_
21-24	3268-3272	that	_	_	_	_
21-25	3273-3281	observed	_	_	_	_
21-26	3282-3284	in	_	_	_	_
21-27	3285-3291	humans	person	giv	coref	25-30
21-28	3292-3298	rather	_	_	_	_
21-29	3299-3303	than	_	_	_	_
21-30	3304-3307	the	abstract[186]	giv[186]	coref	25-25[226_186]
21-31	3308-3315	typical	abstract[186]	giv[186]	_	_
21-32	3316-3328	encephalitic	abstract[186]	giv[186]	_	_
21-33	3329-3336	disease	abstract|abstract[186]	giv|giv[186]	coref	25-15
21-34	3337-3343	course	abstract[186]	giv[186]	_	_
21-35	3344-3352	commonly	_	_	_	_
21-36	3353-3361	reported	_	_	_	_
21-37	3362-3365	for	_	_	_	_
21-38	3366-3370	mice	animal	giv	_	_
21-39	3371-3372	.	_	_	_	_

#Text=Finally , while many flaviviruses share the common ability to antagonize IFN signaling and therefore enhance viral replication , the YFV NS5 is unable to bind murine STAT2 and in contrast to ZIKV and DENV , is unable to engage human STAT2 in murine cells .
22-1	3373-3380	Finally	_	_	_	_
22-2	3381-3382	,	_	_	_	_
22-3	3383-3388	while	_	_	_	_
22-4	3389-3393	many	animal[188]	new[188]	_	_
22-5	3394-3406	flaviviruses	animal[188]	new[188]	_	_
22-6	3407-3412	share	_	_	_	_
22-7	3413-3416	the	abstract[189]	new[189]	_	_
22-8	3417-3423	common	abstract[189]	new[189]	_	_
22-9	3424-3431	ability	abstract[189]	new[189]	_	_
22-10	3432-3434	to	_	_	_	_
22-11	3435-3445	antagonize	_	_	_	_
22-12	3446-3449	IFN	abstract|abstract[191]	giv|new[191]	_	_
22-13	3450-3459	signaling	abstract[191]	new[191]	_	_
22-14	3460-3463	and	_	_	_	_
22-15	3464-3473	therefore	_	_	_	_
22-16	3474-3481	enhance	_	_	_	_
22-17	3482-3487	viral	abstract|abstract[193]	giv|giv[193]	coref|coref	23-7[205_193]|23-7[205_193]
22-18	3488-3499	replication	abstract[193]	giv[193]	_	_
22-19	3500-3501	,	_	_	_	_
22-20	3502-3505	the	abstract[194]|abstract[195]	giv[194]|new[195]	coref|coref|coref|coref	23-21[0_195]|24-10[0_194]|23-21[0_195]|24-10[0_194]
22-21	3506-3509	YFV	abstract[194]|abstract[195]	giv[194]|new[195]	_	_
22-22	3510-3513	NS5	abstract[195]	new[195]	_	_
22-23	3514-3516	is	_	_	_	_
22-24	3517-3523	unable	_	_	_	_
22-25	3524-3526	to	_	_	_	_
22-26	3527-3531	bind	_	_	_	_
22-27	3532-3538	murine	animal|object[197]	new|new[197]	coref|coref|coref|coref	22-41[200_197]|22-44|22-41[200_197]|22-44
22-28	3539-3544	STAT2	object[197]	new[197]	_	_
22-29	3545-3548	and	_	_	_	_
22-30	3549-3551	in	_	_	_	_
22-31	3552-3560	contrast	_	_	_	_
22-32	3561-3563	to	_	_	_	_
22-33	3564-3568	ZIKV	abstract	new	_	_
22-34	3569-3572	and	_	_	_	_
22-35	3573-3577	DENV	abstract	new	_	_
22-36	3578-3579	,	_	_	_	_
22-37	3580-3582	is	_	_	_	_
22-38	3583-3589	unable	_	_	_	_
22-39	3590-3592	to	_	_	_	_
22-40	3593-3599	engage	_	_	_	_
22-41	3600-3605	human	object[200]	giv[200]	coref	23-1[204_200]
22-42	3606-3611	STAT2	object[200]	giv[200]	_	_
22-43	3612-3614	in	_	_	_	_
22-44	3615-3621	murine	substance|object[202]	giv|new[202]	coref|coref|coref|coref	23-1|23-10[207_202]|23-1|23-10[207_202]
22-45	3622-3627	cells	object[202]	new[202]	_	_
22-46	3628-3629	.	_	_	_	_

#Text=Murine STAT2 was demonstrated to repress YFV replication in murine cells , which was correlated with an absence of IFN-α/β-mediated NS5 ubiquitination .
23-1	3630-3636	Murine	animal|object[204]	giv|giv[204]	coref|coref	23-10|23-10
23-2	3637-3642	STAT2	object[204]	giv[204]	_	_
23-3	3643-3646	was	_	_	_	_
23-4	3647-3659	demonstrated	_	_	_	_
23-5	3660-3662	to	_	_	_	_
23-6	3663-3670	repress	_	_	_	_
23-7	3671-3674	YFV	abstract[205]	giv[205]	_	_
23-8	3675-3686	replication	abstract[205]	giv[205]	_	_
23-9	3687-3689	in	abstract[205]	giv[205]	_	_
23-10	3690-3696	murine	abstract[205]|substance|object[207]	giv[205]|giv|giv[207]	_	_
23-11	3697-3702	cells	abstract[205]|object[207]	giv[205]|giv[207]	_	_
23-12	3703-3704	,	_	_	_	_
23-13	3705-3710	which	_	_	_	_
23-14	3711-3714	was	_	_	_	_
23-15	3715-3725	correlated	_	_	_	_
23-16	3726-3730	with	_	_	_	_
23-17	3731-3733	an	abstract[208]	new[208]	_	_
23-18	3734-3741	absence	abstract[208]	new[208]	_	_
23-19	3742-3744	of	abstract[208]	new[208]	_	_
23-20	3745-3761	IFN-α/β-mediated	abstract[208]	new[208]	_	_
23-21	3762-3765	NS5	abstract[208]|abstract|abstract[210]	new[208]|giv|new[210]	_	_
23-22	3766-3780	ubiquitination	abstract[208]|abstract[210]	new[208]|new[210]	_	_
23-23	3781-3782	.	_	_	_	_

#Text=Together , these mouse studies enhance our understanding of YFV dissemination and host control in vivo .
24-1	3783-3791	Together	_	_	_	_
24-2	3792-3793	,	_	_	_	_
24-3	3794-3799	these	abstract[212]	giv[212]	_	_
24-4	3800-3805	mouse	animal|abstract[212]	giv|giv[212]	coref	26-8
24-5	3806-3813	studies	abstract[212]	giv[212]	_	_
24-6	3814-3821	enhance	_	_	_	_
24-7	3822-3825	our	person|abstract[214]	acc|new[214]	_	_
24-8	3826-3839	understanding	abstract[214]	new[214]	_	_
24-9	3840-3842	of	abstract[214]	new[214]	_	_
24-10	3843-3846	YFV	abstract[214]|organization|abstract[216]	new[214]|giv|giv[216]	coref|coref	25-18|25-18
24-11	3847-3860	dissemination	abstract[214]|abstract[216]	new[214]|giv[216]	_	_
24-12	3861-3864	and	_	_	_	_
24-13	3865-3869	host	_	_	_	_
24-14	3870-3877	control	abstract	giv	_	_
24-15	3878-3880	in	_	_	_	_
24-16	3881-3885	vivo	_	_	_	_
24-17	3886-3887	.	_	_	_	_

#Text=These findings are useful for the development of the next generation of small animal disease models for YFV , which should endeavor to recapitulate the disease course seen in humans .
25-1	3888-3893	These	abstract[218]	new[218]	_	_
25-2	3894-3902	findings	abstract[218]	new[218]	_	_
25-3	3903-3906	are	_	_	_	_
25-4	3907-3913	useful	_	_	_	_
25-5	3914-3917	for	_	_	_	_
25-6	3918-3921	the	event[219]	new[219]	_	_
25-7	3922-3933	development	event[219]	new[219]	_	_
25-8	3934-3936	of	event[219]	new[219]	_	_
25-9	3937-3940	the	event[219]|abstract[220]	new[219]|new[220]	_	_
25-10	3941-3945	next	event[219]|abstract[220]	new[219]|new[220]	_	_
25-11	3946-3956	generation	event[219]|abstract[220]	new[219]|new[220]	_	_
25-12	3957-3959	of	event[219]|abstract[220]	new[219]|new[220]	_	_
25-13	3960-3965	small	event[219]|abstract[220]|abstract[223]	new[219]|new[220]|giv[223]	_	_
25-14	3966-3972	animal	event[219]|abstract[220]|person|abstract[223]	new[219]|new[220]|new|giv[223]	_	_
25-15	3973-3980	disease	event[219]|abstract[220]|abstract|abstract[223]	new[219]|new[220]|giv|giv[223]	coref	25-26
25-16	3981-3987	models	event[219]|abstract[220]|abstract[223]	new[219]|new[220]|giv[223]	_	_
25-17	3988-3991	for	event[219]|abstract[220]|abstract[223]	new[219]|new[220]|giv[223]	_	_
25-18	3992-3995	YFV	event[219]|abstract[220]|abstract[223]|abstract	new[219]|new[220]|giv[223]|giv	coref	26-32
25-19	3996-3997	,	_	_	_	_
25-20	3998-4003	which	_	_	_	_
25-21	4004-4010	should	_	_	_	_
25-22	4011-4019	endeavor	_	_	_	_
25-23	4020-4022	to	_	_	_	_
25-24	4023-4035	recapitulate	_	_	_	_
25-25	4036-4039	the	abstract[226]	giv[226]	_	_
25-26	4040-4047	disease	abstract|abstract[226]	giv|giv[226]	_	_
25-27	4048-4054	course	abstract[226]	giv[226]	_	_
25-28	4055-4059	seen	_	_	_	_
25-29	4060-4062	in	_	_	_	_
25-30	4063-4069	humans	person	giv	_	_
25-31	4070-4071	.	_	_	_	_

#Text=Thus , the generation of an immunocompetent mouse model would be beneficial , which could be realized by knocking out downstream specific anti-YFV effectors that directly inhibit differential aspects of the YFV lifecycle , rather than upstream master-regulators of the antiviral response .
26-1	4072-4076	Thus	_	_	_	_
26-2	4077-4078	,	_	_	_	_
26-3	4079-4082	the	abstract[228]	new[228]	_	_
26-4	4083-4093	generation	abstract[228]	new[228]	_	_
26-5	4094-4096	of	abstract[228]	new[228]	_	_
26-6	4097-4099	an	abstract[228]|abstract[230]	new[228]|new[230]	_	_
26-7	4100-4115	immunocompetent	abstract[228]|abstract[230]	new[228]|new[230]	_	_
26-8	4116-4121	mouse	abstract[228]|animal|abstract[230]	new[228]|giv|new[230]	_	_
26-9	4122-4127	model	abstract[228]|abstract[230]	new[228]|new[230]	_	_
26-10	4128-4133	would	_	_	_	_
26-11	4134-4136	be	_	_	_	_
26-12	4137-4147	beneficial	_	_	_	_
26-13	4148-4149	,	_	_	_	_
26-14	4150-4155	which	_	_	_	_
26-15	4156-4161	could	_	_	_	_
26-16	4162-4164	be	_	_	_	_
26-17	4165-4173	realized	_	_	_	_
26-18	4174-4176	by	_	_	_	_
26-19	4177-4185	knocking	_	_	_	_
26-20	4186-4189	out	_	_	_	_
26-21	4190-4200	downstream	abstract[231]	new[231]	_	_
26-22	4201-4209	specific	abstract[231]	new[231]	_	_
26-23	4210-4218	anti-YFV	abstract[231]	new[231]	_	_
26-24	4219-4228	effectors	abstract[231]	new[231]	_	_
26-25	4229-4233	that	_	_	_	_
26-26	4234-4242	directly	_	_	_	_
26-27	4243-4250	inhibit	_	_	_	_
26-28	4251-4263	differential	abstract[232]	new[232]	_	_
26-29	4264-4271	aspects	abstract[232]	new[232]	_	_
26-30	4272-4274	of	abstract[232]	new[232]	_	_
26-31	4275-4278	the	abstract[232]|abstract[234]	new[232]|new[234]	_	_
26-32	4279-4282	YFV	abstract[232]|abstract|abstract[234]	new[232]|giv|new[234]	_	_
26-33	4283-4292	lifecycle	abstract[232]|abstract[234]	new[232]|new[234]	_	_
26-34	4293-4294	,	_	_	_	_
26-35	4295-4301	rather	_	_	_	_
26-36	4302-4306	than	_	_	_	_
26-37	4307-4315	upstream	abstract[235]	new[235]	_	_
26-38	4316-4333	master-regulators	abstract[235]	new[235]	_	_
26-39	4334-4336	of	abstract[235]	new[235]	_	_
26-40	4337-4340	the	abstract[235]|abstract[236]	new[235]|new[236]	_	_
26-41	4341-4350	antiviral	abstract[235]|abstract[236]	new[235]|new[236]	_	_
26-42	4351-4359	response	abstract[235]|abstract[236]	new[235]|new[236]	_	_
26-43	4360-4361	.	_	_	_	_

#Text=Screening approaches could identify such factors .
27-1	4362-4371	Screening	abstract[237]	new[237]	_	_
27-2	4372-4382	approaches	abstract[237]	new[237]	_	_
27-3	4383-4388	could	_	_	_	_
27-4	4389-4397	identify	_	_	_	_
27-5	4398-4402	such	abstract[238]	new[238]	_	_
27-6	4403-4410	factors	abstract[238]	new[238]	_	_
27-7	4411-4412	.	_	_	_	_
